TrialSignal transduction and targeted therapy2026

Perioperative penpulimab-based combination therapy in patients with resectable non-small cell lung cancer (ALTER-L043): an open-label, multicenter, randomized, phase II trial.

Meng Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.